Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04761198 | A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors | PHASE1/PHASE2 | COMPLETED | 76 | — | — | Mar 1, 2021 | Oct 1, 2023 | Mar 16, 2025 | - | — |
| Name | Type | Description |
|---|---|---|
| Etigilimab | DRUG | IV infusion of IV etigilimab every 2 weeks |
| Nivolumab | DRUG | IV infusion of nivolumab every 2 weeks |